Selectivity of Oncolytic Viral Replication Prevents Antiviral Immune Response and Toxicity, but Does Not Improve Antitumoral Immunity
Open Access
- 1 November 2010
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 18 (11) , 1972-1982
- https://doi.org/10.1038/mt.2010.163
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Targeting of p53-Transcriptional Dysfunction by Conditionally Replicating Adenovirus Is Not Limited by p53-HomologuesMolecular Therapy, 2010
- Viral and nonviral factors causing nonspecific replication of tumor- and tissue-specific promoter-dependent oncolytic adenovirusesMolecular Therapy, 2005
- MyD88 Expression Is Required for Efficient Cross-Presentation of Viral Antigens from Infected CellsJournal of Virology, 2005
- Toll-like receptor 3 promotes cross-priming to virus-infected cellsNature, 2005
- Protein Transduction Domains Fused to Virus Receptors Improve Cellular Virus Uptake and Enhance Oncolysis by Tumor-Specific Replicating VectorsJournal of Virology, 2004
- Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathwaysCancer Gene Therapy, 2003
- E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor modelsNature Biotechnology, 2003
- Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacyMolecular Therapy, 2003
- The Hallmarks of CancerCell, 2000
- ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agentsNature Medicine, 1997